scholarly journals A new self‐reported measure of disease severity of scalp hair loss in alopecia areata

2020 ◽  
Vol 183 (6) ◽  
pp. 986-987
Author(s):  
F. Rencz
Keyword(s):  
Disease Severity ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Scalp Hair

Role of adiponectin and leptin in patients with alopecia areata with scalp hair loss

2020 ◽  
Author(s):  
Gamze Serarslan ◽  
Oğuzhan Özcan ◽  
Ebru Okyay ◽  
Bahar Ünlü ◽  
Mehmet Karadağ
Keyword(s):  
Hair Loss ◽  
Alopecia Areata ◽  
Scalp Hair

Scalp hair loss after transsphenoidal adenomectomy in patients with acromegaly

2013 ◽  
Vol 79 (3) ◽  
pp. 386-393 ◽  
Author(s):  
Shozo Yamada ◽  
Noriaki Fukuhara ◽  
Hiroshi Nishioka ◽  
Mitsuo Yamaguchi-Okada ◽  
Akira Takeshita ◽  
...  
Keyword(s):  
Hair Loss ◽  
Scalp Hair ◽  
Transsphenoidal Adenomectomy

Hair Growth in a Patient with Alopecia Areata on Tocilizumab

2021 ◽  
pp. 1-5
Author(s):  
Chloe J. Walker ◽  
Kelly E. Flanagan ◽  
James T. Pathoulas ◽  
Isabel Pupo Wiss ◽  
Maryanne M. Senna
Keyword(s):  
Monoclonal Antibody ◽  
Autoimmune Disease ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Interleukin 6 ◽  
Hair Growth ◽  
Posterior Uveitis ◽  
Case Presentation ◽  
Antibody Targeting ◽  
Growth Changes

<b><i>Introduction:</i></b> Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. <b><i>Case Presentation:</i></b> Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. <b><i>Discussion:</i></b> Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.

scholarly journals “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Natalie V. J. Aldhouse ◽  
Helen Kitchen ◽  
Sarah Knight ◽  
Jake Macey ◽  
Fabio P. Nunes ◽  
...  
Keyword(s):  
Hair Loss ◽  
Alopecia Areata ◽  
Disease Recurrence ◽  
Structured Interview ◽  
Emotional Impact ◽  
Psychosocial Effects ◽  
Psychosocial Burden ◽  
Qualitative Interview Study ◽  
Interview Guide ◽  
Expert Clinician

Abstract Background Alopecia areata (AA) is characterized by hair loss that can affect the scalp and body. This study describes the psychosocial burden of AA. Methods Participants diagnosed with AA who had experienced ≥50% scalp hair loss according to the Severity of Alopecia Tool (SALT) were identified by clinicians. A semi-structured interview guide, developed with expert clinician input, included open-ended questions to explore patients’ experiences of living with AA. Data were thematically analyzed to identify concepts and relationships. Results Participants (n = 45, 58% female, mean age 33.3 years [range 15–72], mean SALT 67.2 [range 0–100]) described the AA diagnosis as “devastating”. Both males and females reported emotional and psychological impacts of AA including feeling sad/depressed (n = 21), embarrassed/ashamed (n = 10) and angry/frustrated (n = 3). Patients felt helpless (n = 5) due to the unpredictability of disease recurrence, and anxious (n = 19) about judgement from others. Many patients avoided social situations (n = 18), which impaired relationships and increased isolation. Coping strategies included concealment of hair loss through wigs or make-up, although fear of the displacement of these coverings also caused anxiety and the avoidance of activities that could result in scalp exposure (n = 22). Some patients became more accepting of AA over time, which lessened the emotional impact, though efficacious treatment was still desired. A conceptual framework was developed, and a conceptual model was created to depict the relationship between the physical signs/symptoms and the associated psychosocial effects of AA. Conclusion AA impairs patients’ emotional and psychological wellbeing, relationships and lifestyles. Greater disease awareness and effective treatments are needed.

scholarly journals COVID-19 Pandemic Impact on Severe Alopecia Areata Patients

2021 ◽  
pp. 1-5
Author(s):  
Mehdi Gheisari ◽  
Khatere Zahedi ◽  
Zohreh Tehranchinia ◽  
Hamideh Moravvej ◽  
Fahimeh Abdollahimajd ◽  
...  
Keyword(s):  
Dose Reduction ◽  
Chronic Stress ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Systemic Therapy ◽  
Demographic Data ◽  
Severe Infection ◽  
Drug Dose ◽  
The Other ◽  
Protective Measures

<b><i>Introduction:</i></b> The pandemic of COVID-19 has several implications for patients with chronic stress-sensitive diseases such as alopecia areata (AA). On the other hand, the vulnerability of AA patients using immunosuppressives to a more severe infection is in the shadow of ambiguity. This teledermatology study aimed to evaluate the course and outcome of AA in patients during this challenging period. <b><i>Methods:</i></b> Patients with AA who had previously received systemic therapy included in this study. Information about demographic data, AA history, characteristics, and treatments, hair loss progression, Corona Disease Anxiety Scale (CDAS), adherence to protective measures against the COVID-19, possible infection, and its features obtained via a telephone call. <b><i>Results:</i></b> A total of 57 patients participated. The majority (84.2%) of the participants had mild anxiety assessed by CDAS. Two patients (3.5%) had got infected with COVID-19. Twenty-one (36.8%) participants experienced hair loss progression. Hair loss progression correlated with drug dose reduction (OR: 46.09, 95% CI 5.48–387.14, <i>p</i> &#x3c; 0.001) although it did not influence by the level of anxiety evaluated by the CDAS (<i>p</i> &#x3e; 0.05). <b><i>Conclusion:</i></b> The anxiety perceived by severe AA patients about COVID-19 is mild; however, many experience hair loss progressions owing to their drug dose reduction.

scholarly journals Pharmaceutico-Analytical study of Karanjadi Taila and its conversion into cream

2020 ◽  
Vol 5 (05) ◽  
pp. 245-249
Author(s):  
Sachin S. Sheth ◽  
Gangaprasad R. Asore ◽  
Kiran Sudhakar Darade
Keyword(s):  
Present Article ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Analytical Study ◽  
Chief Complaint ◽  
Point Of View ◽  
Special Importance ◽  
Analytical Results

Karanjadi Taila is medicated oil used in Ayurveda for Indralupta (Alopecia). Indralupta comes under Kshudra Roga which is characterized by loss of hair it can be correlated with Alopecia areata which is having chief complaint of hair loss on body especially on scalp. The aim of the present study is to do physic-chemical standards for the above Taila and its conversion into Karanjadi Taila cream. These two formulations have a special importance from pharmaceutical point of view when compared to usual Tailas or cream. In present article, we are trying to study analytical results of Karanjadi Taila w.s.r. to Karanjadi Taila cream.

Sign in / Sign up

Export Citation Format

Share Document